Viral vectors in cancer immunotherapy: Which vector for which strategy?

Current Gene Therapy

Volumn 8, Issue 2, 2008, Pages 66-78

  Collins, Sara A ^a   Guinn, Barbara Ann ^b   Harrison, Patrick T ^c   Scallan, Martina F ^c   O'Sullivan, Gerald C ^a   Tangney, Mark ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Adeno associated virus; Adenovirus; Dendritic cell; Gene therapy; Herpes simplex virus; Lentivirus; Retrovirus; Semliki forest virus

Indexed keywords

ADENOVIRUS VECTOR; B7 ANTIGEN; BETA INTERFERON; CALRETICULIN; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; DEATH RECEPTOR 5; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA UROGASTRONE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 7; LENTIVIRUS VECTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELACINE; MONOCLONAL ANTIBODY; NEU DIFFERENTIATION FACTOR; ONYVAX P; PARVOVIRUS VECTOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN E7; RETROVIRUS VECTOR; UNINDEXED DRUG; VIRUS ONCOLYSATE; VIRUS VECTOR;

ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; BLADDER CARCINOMA; CANCER GENE THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; DNA MODIFICATION; ENCAPSULATION; GENE CASSETTE; GENETIC IMMUNIZATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GLIOMA; HERPES SIMPLEX VIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; IN VITRO GENE TRANSFER; IN VIVO GENE TRANSFER; LUNG ADENOCARCINOMA; MAGNETIC FIELD; MAGNETOFECTION; MELANOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROSTATE CANCER; PROTEIN SECRETION; REGULATORY T LYMPHOCYTE; REVIEW; SEMLIKI FOREST ALPHAVIRUS; T LYMPHOCYTE ACTIVATION; TARGET CELL; TUMOR IMMUNITY; TUMOR REGRESSION; ULTRASOUND; ULTRASOUND BASED GENETIC TRANSFECTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WHOLE CELL; ANIMAL; GENE THERAPY; GENE VECTOR; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; NEOPLASM; VIRUS;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; ANIMALIA; LENTIVIRUS; SEMLIKI FOREST VIRUS; SIMPLEXVIRUS;

ANIMALS; CANCER VACCINES; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; VIRUSES;

EID: 45849128013     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652308784049345     Document Type: Review

References (173)

1. Griesenbach U, Geddes DM, Alton EW. Gene therapy progress and prospects: cystic fibrosis. Gene Ther 13: 1061-7 (2006).
2. Cavazzana-Calvo M, Lagresle C, Hacein-Bey-Abina S, Fischer A. Gene therapy for severe combined immunodeficiency. Annu Rev Med 56: 585-602 (2005).
3. Chamberlain JS. Gene therapy of muscular dystrophy. Hum Mol Genet 11: 2355-62 (2002).
4. Tangney M, Casey G, Larkin JO, et al. Non-viral in vivo immune gene therapy of cancer: combined strategies for treatment of systemic disease. Cancer Immunol Immunother 11: 1443-50 (2006).
5. Collins CG, Tangney M, Larkin JO, et al. Local gene therapy of solid tumors with GM-CSF and B7-1 eradicates both treated and distal tumors. Cancer Gene Ther 13: 1061-71 (2006).
6. Toda, M, Martuza RL, Rabkin SD. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor. Mol Ther 2: 324-9 (2000).
7. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4: 11-22 (2004).
8. Barzon L, Bonaguro R, Castagliuolo I, et al. Gene therapy of thyroid cancer via retrovirally-driven combined expression of human interleukin-2 and herpes simplex virus thymidine kinase. Eur J Endocrinol 148: 73-80 (2003).
9. Barajas M, Mazzolini G, Gcnove G, et al. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. Hepatology 33: 52-61 (2001).
10. Caruso M, Pham-Nguyen K, Kwong YL, et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Nad Acad Sci U S A 93: 11302-6 (1996).
11. Divino CM, Chen SH, Yang W, et al. Anti-tumor immunity induced by interleukin-12 gene therapy in a metastatic model of breast cancer is mediated by natural killer cells. Breast Cancer Res Treat 60: 129-34 (2000).
12. Liu Y, Ehtesham M, Samoto K, et al. In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma. Cancer Gene Ther 9: 9-15 (2002).
13. Nasu Y, Bangma CH, Hull GW, et al. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Ther 6: 338-49 (1999).
14. Asselin-Paturel C, Lassau N, Guinebretiere JM, et al. Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography. Gene Ther 6: 606-15 (1999).
15. Chikkanna-Gowda CP, Sheahan BJ, Fleeton MN, Atkins GJ. Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12. Gene Ther 12: 1253-63 (2005).
16. D'Angelica M, Karpoff H, Halterman M, et al. In vivo interleukin-2 gene therapy of established tumors with herpes simplex amplicon vectors. Cancer Immunol Immunother 47: 265-71 (1999).
17. Zhang JF, Hu C, Geng Y, Blatt LM, Taylor MW. Gene therapy with an adeno-associated virus carrying an interferon gene results in tumor growth suppression and regression. Cancer Gene Ther 3: 31-8 (1996).
18. Yoshida J, Mizuno M, Nakahara N, Colosi P. Antitumor effect of an adeno-associated virus vector containing the human interferon-beta gene on experimental intracranial human glioma. Jpn J Cancer Res 93: 223-8 (2002).
19. Ramarathinam L, Castle M, Wu Y, Liu Y. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/ BB1 in the induction, recruitment, and effector function of antittunor T cells. J Exp Med 179: 1205-14 (1994).
20. Borrello I, Pardoll D. GM-CSF-based cellular vaccines: a review of the clinical experience. Cytokine Growth Factor Rev 13: 185-93 (2002).
21. Chen L, Ashe S, Brady WA, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71: 1093-102 (1992).
22. Tsuji H, Kawaguchi S, Wada T, et al. Adenovirus-mediated in vivo B7-1 gene transfer induces anti-tumor immunity against pre-established primary tumor and pulmonary metastasis of rat osteosarcoma. Cancer Gene Ther 9: 747-55 (2002).
23. Loskog AS, Fransson ME, Totterman TT. AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model. Clin Cancer Res 11: 8816-21 (2005).
24. Kutubuddin M, Federoff HJ, Challita-Eid PM, et al. Eradication of pre-established lymphoma using herpes simplex virus amplicon vectors. Blood 93: 643-54 (1999).
25. Tolba KA, Bowers WJ, Muller J, et al. Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity. Cancer Res 62: 6545-51 (2002).
26. Gilboa E. The makings of a tumor rejection antigen. Immunity 11: 263-70 (1999).
27. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10: 281-7 (1999).
28. Van den Eynde B, Brichard VG. New tumor antigens recognized by T cells. Curr Opin Immunol 7: 674-81 (1995).
29. Goldenberg DM, Sharkey RM, Primus FJ. Carcinoembryonic antigen in histopathology: immunoperoxidase staining of conventional tissue sections. J Natl Cancer Inst 57: 11-22 (1976).
30. Baxevanis CN, Sotiropoulou PA, Sotiriadou NN, Papamichail M. Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy. Cancer Immunol Immunother 53: 166-75 (2004).
31. Horig H, Lee CS, Kaufman HL. Prostate-specific antigen vaccines for prostate cancer. Expert Opin Biol Ther 2: 395-408 (2002).
32. Atkins GJ, Smyth JW, Fleeton MN, Galbraith SE, Sheahan BJ. Alphaviruses and their derived vectors as anti-tumor agents. Curr Cancer Drug Targets 4: 597-607 (2004).
33. Gomez-Gutierrez JG, Elpek KG, Montes de Oca-Luna R, et al. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunol Immunother 55: 958-68 (2006).
34. Dullaers M, Van Meirvenne S, Heirman C, et al. Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther 13: 630-40 (2006).
35. Li Q, Kay MA, Finegold M, Stratford-Perricaudet LD, Woo SL. Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum Gene Ther 4: 403-9 (1993).
36. Quantin B, Perricaudet LD, Tajbakhsh S, Mandel JL. Adenovirus as an expression vector in muscle cells in vivo. Proc Natl Acad Sci U S A 89: 2581-4 (1992).
37. Kafri T, Morgan D, Krahl T, et al. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc Natl Acad Sci USA 95: 11377-82 (1998).
38. Mack CA, Song WR, Carpenter H, et al. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Ther 8: 99-109 (1997).
39. Yang Y, Nunes FA, Berencsi K, et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A 91: 4407-11 (1994).
40. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80: 148-58 (2003).
41. Raper SE, Yudkoff M, Chirmule N, et al. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther 13: 163-75 (2002).
42. Kochanek S, Clemens PR, Mitani K, et al. A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci U S A 93: 5731-6 (1996).
43. Kochanek S, Schiedner G, Volpers C. High-capacity 'gutless' adenoviral vectors. Curr Opin Mol Ther 3: 454-63 (2001).
44. Parks RJ, Chen L, Anton M, et al. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A 93: 13565-70 (1996).
45. Kelly Jnr. TJ. Adenovirus DNA replication. New York: Plenum; 1984.
46. Le HT, Yu QC, Wilson JM, Croyle MA. Utility of PEGylated recombinant adeno-associated viruses for gene transfer. J Control Release 108: 161-77 (2005).
47. Yotnda P, Chen DH Chiu W, et al. Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol Ther 5: 233-41 (2002).
48. Croyle MA, Chirmule N, Zhang Y, Wilson JM. "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol 75: 4792-801 (2001).
49. Croyle MA, Chirmule N, Zhang Y, Wilson JM. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum Gene Ther 13: 1887-900 (2002).
50. Croyle MA, Le HT, Linse KD, et al. PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile. Gene Ther 12:579-87 (2005).
51. Mok H, Palmer DJ, Ng P, Barry MA. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther 11: 66-79 (2005).
52. Sandrin V, Russell SJ, Cosset FL. Targeting retroviral and lentiviral vectors. Curr Top Microbiol Immunol 281: 137-78 (2003).
53. Choi VW, McCarty DM, Samulski RJ. AAV hybrid serotypes: improved vectors for gene delivery. Curr Gene Ther 5: 299-310 (2005).
54. Kasahara N, Dozy AM, Kan YW. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 266: 1373-6 (1994).
55. Han X, Kasahara N, Kan YW. Ligand-directed retroviral targeting of human breast cancer cells. Proc Natl Acad Sci U S A 92: 9747-51 (1995).
56. Cosset FL, Morling FJ, Takeuchi Y, et al. Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol 69: 6314-22 (1995).
57. Marin M, Noel D, Valsesia-Wittman S, et al. Targeted infection of human cells via major histocompatibility complex class I molecules by Moloney murine leukemia virus-derived viruses displaying single-chain antibody fragment-envelope fusion proteins. J Virol 70: 2957-62 (1996).
58. Bartlett JS, Kleinschmidt J, Boucher RC, Samulski RJ. Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody. Nat Biotechnol 17: 181-6 (1999).
59. Ponnazhagan S, Mahendra G, Kumar S, Thompson JA, Castillas M, Jr. Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands. J Virol 76: 12900-7 (2002).
60. Buning H, Ried MU, Perabo L, et al. Receptor targeting of adeno-associated virus vectors. Gene Ther 10: 1142-51 (2003).
61. Lee CH, Liu M, Sie KL, Lee MS. Prostate-specific antigen promoter driven gene therapy targeting DNA polymerase-alpha and topoisomerase II alpha in prostate cancer. Anticancer Res 16: 1805-11 (1996).
62. Martiniello-Wilks R, Garcia-Aragon J, Daja MM, et al. In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors. Hum Gene Ther 9: 1617-26 (1998).
63. Shay JW, Wright WE. Telomerase: a target for cancer therapeutics. Cancer Cell 2: 257-65 (2002).
64. Brand K, Loser P, Arnold W, Bartels T, Strauss M. Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach. Gene Ther 5: 1363-71 (1998).
65. Cao G, Kuriyama S, Gao J, et al. Effective and safe gene therapy for colorectal carcinoma using the cytosine deaminase gene directed by the carcinoembryonic antigen promoter. Gene Ther 6: 83-90 (1999).
66. Cox GA, Cole NM, Matsumura K, et al. Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity. Nature 364: 725-9 (1993).
67. Su H, Chang JC, Xu SM, Kan YW. Selective killing of AFP-positive hepatocellular carcinoma cells by adeno-associated virus transfer of the herpes simplex virus thymidine kinase gene. Hum Gene Ther 7: 463-70 (1996).
68. Shevtsova Z, Malik JM, Michel U, Bahr M, Kugler S. Promoters and serotypes: targeting of adeno-associated virus vectors for gene transfer in the rat central nervous system in vitro and in vivo. Exp Physiol 90: 53-9 (2005).
69. Hughes C, Galea-Lauri J, Farzaneh F, Darling D. Streptavidin paramagnetic particles provide a choice of three affinity-based capture and magnetic concentration strategies for retroviral vectors. Mol Ther 3: 623-30 (2001).
70. Mah C, Fraites TJ, Jr., Zolotukhin I, et al. Improved method of recombinant AAV2 delivery for systemic targeted gene therapy. Mol Ther 6: 106-12 (2002).
71. Pandori M, Hobson D, Sano T. Adenovirus-microbead conjugates possess enhanced infectivity: a new strategy for localized gene delivery. Virology 299: 204-12 (2002).
72. Taylor SL, Rahim AA, Bush NL, Bamber JC, Porter CD. Targeted retroviral gene delivery using ultrasound. J Gene Med 9: 77-87 (2007).
73. Kim HJ, Greenleaf JF, Kinnick RR, Bronk JT, Bolander ME. Ultrasound-mediated transfection of mammalian cells. Hum Gene Ther 7: 1339-46 (1996).
74. Porter CD. Rescue of retroviral envelope fusion deficiencies by cationic liposomes. J Gene Med 4: 622-33 (2002).
75. Dillman RO, DeLeon C, Beutel LD, et al. Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma. Crit Rev Oncol Hematol 39: 115-23 (2001).
76. Copier J, Dalgleish A. Overview of tumor cell-based vaccines. Int Rev Immunol 25: 297-319 (2006).
77. Doehn C, Bohmer T, Jocham D. Technology evaluation: Onyvax-P, Onyvax. Curr Opin Mol Ther 7: 511-9 (2005).
78. Chan L, Hardwick N, Darling D, et al. IL-2/B7.1 (CD80) fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML. Mol Ther 11: 120-31 (2005).
79. Koya RC, Kasahara N, Pullarkat V, Levine AM, Stripecke R. Transduction of acute myeloid leukemia cells with third generation self-inactivating lentiviral vectors expressing CD80 and GM-CSF: effects on proliferation, differentiation, and stimulation of allogeneic and autologous anti-leukemia immune responses. Leukemia 16: 1645-54 (2002).
80. Hege KM, Jooss K, Pardoll D. GM-CSF gene-modifed cancer cell immunotherapies: of mice and men. Int Rev Immunol 25: 321-52 (2006).
81. Ohashi K, Kobayashi G, Fang S, et al. Surgical excision combined with autologous whole tumor cell vaccination is an effective therapy for murine neuroblastoma. J Pediatr Surg 41: 1361-8 (2006).
82. Grant JF, Iwasawa T, Sinn HW, et al. Induction of protective immunity to RM-1 prostate cancer cells with ALVAC-II-2/II-12/TNFa combination therapy. Int J Cancer 119: 2632-41 (2006).
83. Pandha H, Eaton J, Greenhalgh R, Soars D, Dalgleish A. Immunotherapy of murine prostate cancer using whole tumor cells killed ex vivo by herpes simplex viral thymidine kinase/ganciclovir suicide gene therapy. Cancer Gene Ther 12: 572-8 (2005).
84. Dyall J, Latouche JB, Schnell S, Sadelain M. Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. Blood 97: 114-21 (2001).
85. Esslinger C, Chapatte L, Finke D, et al. In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. J Clin Invest 111: 1673-81 (2003).
86. Lizee G, Gonzales MI, Topalian SL. Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells. Hum Gene Ther 15: 393-404 (2004).
87. Metharom P, Ellem KA, Schmidt C, Wei MQ. Lentiviral vector-mediated tyrosinase-related protein 2 gene transfer to dendritic cells for the therapy of melanoma. Hum Gene Ther 12: 2203-13 (2001).
88. Sharma S, Batra RK, Yang SC, et al. Interleukin-7 gene-modified dendritic cells reduce pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Hum Gene Ther 14: 1511-24 (2003).
89. Chen Y, Emtage P, Zhu Q, et al. Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12. Gene Ther 8: 316-23 (2001).
90. Ribas A, Butterfield LH, Hu B, et al. Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells. J Immunother 23: 59-66 (2000).
91. Willis RA, Bowers WJ, Turner MJ, et al. Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice. Hum Gene Ther 12: 1867-79 (2001).
92. Yamanaka R, Tsuchiya N, Yajima N, et al. Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12. J Neurosurg 99: 746-53 (2003).
93. Yamanaka R, Zullo SA, Tanaka R, et al. Induction of a therapeutic antitumor immunological response by intratumoral injection of genetically engineered Semliki Forest virus to produce interleukin-12. Neurosurg Focus 9: e7 (2000).
94. Hudson PJ, Souriau C. Engineered antibodies. Nat Med 9: 129-34 (2003).
95. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 48: 7022-32 (1988).
96. Ye Z, Hellstrom I, Hayden-Ledbetter M, et al. Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Nat Med 8: 343-8 (2002).
97. Shi J, Liu Y, Zheng Y, et al. Therapeutic expression of an anti-death receptor 5 single-chain fixed-variable region prevents tumor growth in mice. Cancer Res 66: 11946-53 (2006).
98. Lamers CH, Sleijfer S, Willemsen RA, et al. Adoptive immunogene therapy of cancer with single chain antibody [scFv(Ig)] gene modified T lymphocytes. J Biol Regul Homeost Agents 18: 134-40 (2004).
99. Naslund TI, Uyttenhove C, Nordstrom EK, et al. Comparative prime-boost vaccinations using semliki forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor. J Immunol 178: 6761-9 (2007).
100. Cavazzana-Calvo M, Fischer A. Efficacy of gene therapy for SCID is being confirmed. Lancet 364: 2155-6 (2004).
101. Check E. A tragic setback. Nature 420: 116-8 (2002).
102. Pang S, Koyanagi Y, Miles S, et al. High levels of unintegrated HIV-1 DNA in brain tissue of AIDS dementia patients. Nature 343: 85-9 (1990).
103. Pauza CD, Galindo JE, Richman DD. Reinfection results in accumulation of unintegrated viral DNA in cytopathic and persistent human immunodeficiency virus type 1 infection of CEM cells. J Exp Med 172: 1035-42 (1990).
104. Robinson HL, Zinkus DM. Accumulation of human immunodeficiency virus type 1 DNA in T cells: results of multiple infection events. J Virol 64: 4836-41 (1990).
105. Cara A, Reitz MS, Jr. New insight on the role of extrachromosomal retroviral DNA. Leukemia 11: 1395-9 (1997).
106. Terskikh AV, Ershler MA, Drize NJ, Nifontova IN, Chertkov JL. Long-term persistence of a nonintegrated lentiviral vector in mouse hematopoietic stem cells. Exp Hematol 33: 873-82 (2005).
107. Brown HE, Chen H, Engelman A. Structure-based mutagenesis of the human immunodeficiency virus type 1 DNA attachment site: effects on integration and cDNA synthesis. J Virol 73: 9011-20 (1999).
108. Cereseto A, Manganaro L, Gutierrez MI, et al. Acetylation of HIV-1 integrase by p300 regulates viral integration. EMBO J 24: 3070-81 (2005).
109. Johnson AA, Santos W, Pais GC, et al. Integration requires a specific interaction of the donor DNA terminal 5′-cytosine with glutamine 148 of the HIV-1 integrase flexible loop. J Biol Chem 281: 461-7 (2006).
110. Nightingale SJ, Hollis RP, Pepper KA, et al. Transient gene expression by nonintegrating lentiviral vectors. Mol Ther 13: 1121-32 (2006).
111. Hazuda DJ, Young SD, Guare JP, et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 305: 528-32 (2004).
112. Hazuda DJ, Felock P, Witmer K et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287: 646-50 (2000).
113. Bushman FD. Targeting survival: integration site selection by retroviruses and LTR-retrotransposons. Cell 115: 135-8 (2003).
114. Recillas-Targa F, Valadez-Graham V, Farrell CM. Prospects and implications of using chromatin insulators in gene therapy and transgenesis. Bioessays 26: 796-807 (2004).
115. Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favored targets for MLV integration. Science 300: 1749-51 (2003).
116. Johnston JC, Gasmi M, Lim LE, et al. Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors. J Virol 73: 4991-5000 (1999).
117. Mitrophanous K, Yoon S, Rohll J, et al. Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther 6: 1808-18 (1999).
118. Poeschla EM, Wong-Staal F, Looney DJ. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat Med 4: 354-7 (1998).
119. Young SM, Jr., McCarty DM, Degtyareva N, Samulski RJ. Roles of adeno-associated virus Rep protein and human chromosome 19 in site-specific recombination. J Virol 74: 3953-66 (2000).
120. Nakai H, Montini E, Fuess S, et al. AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet 34: 297-302 (2003).
121. Bell P, Moscioni AD, McCarter RJ, et al. Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. Mol Ther 14: 34-44 (2006).
122. Donsante A, Miller DG, Li Y, et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science 317: 477 (2007).
123. Liu Q, Perez CF, Wang Y. Efficient site-specific integration of large transgenes by an enhanced herpes simplex virus/adenoassociated virus hybrid amplicon vector. J Virol 80: 1672-9 (2006).
124. Oehmig A, Cortes ML, Perry KF, et al. Integration of active human beta-galactosidase gene (100 kb) into genome using HSV/AAV amplicon vector. Gene Ther 14: 1078-91 (2007).
125. Zhang C, Cortez NG, Berns KI. Characterization of a Bipartite Recombinant Adeno-Associated Viral Vector for Site-Specific Integration. Hum Gene Ther: (2007).
126. Alain T, Hirasawa K, Pon KJ, et al. Reovirus therapy of lymphoid malignancies. Blood 100: 4146-53 (2002).
127. Hirasawa K, Nishikawa SG, Norman KL, et al. Oncolytic reovirus against ovarian and colon cancer. Cancer Res 62: 1696-701 (2002).
128. Norman KL, Coffey MC, Hirasawa Y, et al. Reovirus oncolysis of human breast cancer. Hum Gene Ther 13: 641-52 (2002).
129. Mullen JT, Tanabe KK. Viral oncolysis. Oncologist 7: 106-19 (2002).
130. Phuangsab A, Lorence RM, Reichard KW, Peeples ME, Walter RJ. Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. Cancer Lett 172: 27-36 (2001).
131. Stojdl DF, Lichty B, Knowles S, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6: 821-5 (2000).
132. Stojdl DF, Lichty BD, tenOever BR, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4: 263-75 (2003).
133. Haag A, Menten P, Van Damme J, et al. Highly efficient transduction and expression of cytokine genes in human tumor cells by means of autonomous parvovirus vectors; generation of antitumor responses in recipient mice. Hum Gene Ther 11: 597-609 (2000).
134. Herrero YCM, Cornelis JJ, Herold-Mende C, et al. Parvovirus H-1 infection of human glioma cells leads to complete viral replication and efficient cell killing. Int J Cancer 109: 76-84 (2004).
135. Moehler M, Blechacz B, Weiskopf N, et al. Effective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H1 and derived vectors. Cancer Gene Ther 8: 158-67 (2001).
136. Savage HE, Rossen RD, Hersh EM, et al. Antibody development to viral and allogeneic tumor cell-associated antigens in patients with malignant melanoma and ovarian carcinoma treated with lysates of virus-infected tumor cells. Cancer Res 46: 2127-33 (1986).
137. Sinkovics JG. Viral oncolysates as human tumor vaccines. Int Rev Immunol 7: 259-87 (1991).
138. Wallack MK, Meyer M, Bourgoin A, et al. A preliminary trial of vaccinia oncolysates in the treatment of recurrent melanoma with serologic responses to the treatment. J Biol Response Mod 2: 586-96 (1983).
139. Wallack MK, Michaelides M. Serologic response to human melanoma lines from patients with melanoma undergoing treatment with vaccinia melanoma oncolysates. Surgery 96: 791-800 (1984).
140. Wallack MK, Sivanandham M, Balch CM, et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 187: 69-77 (1998).
141. Batliwalla FM, Bateman BA, Serrano D, et al. A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol Med 4: 783-94 (1998).
142. Eder JP, Kantoff PW, Roper K, et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 6: 1632-8 (2000).
143. Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 18: 3964-73 (2000).
144. Bristol JA, Zhu M, Ji H, et al. In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF. Mol Ther 7: 755-64 (2003).
145. Zhang JF, Hu C, Geng Y, et al. Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy. Proc Natl Acad Sci USA 93: 4513-8 (1996).
146. Choi KJ, Kim JH, Lee YS, et al. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Gene Ther 13: 1010-20 (2006).
147. Andreansky S, He B, van Cott J, et al. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther 5: 121-30 (1998).
148. Parker JN, Gillespie GY, Love CE, et al. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci USA 97: 2208-13 (2000).
149. Wong RJ, Patel SG, Kim S, et al. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum Gene Ther 12: 253-65 (2001).
150. Aarts WM, Schlom J, Hodge JW. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res 62: 5770-7 (2002).
151. Garnett CT, Greiner JW, Tsang KY, et al. TRICOM vector based cancer vaccines. Curr Pharm Des 12: 351-61 (2006).
152. Yu P, Lee Y, Liu W, et al. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 201: 779-91 (2005).
153. Terabe M, Berzofsky JA. Immunoregulatory T cells in tumor immunity. Curr Opin Immunol 16: 157-62 (2004).
154. Elia L, Aurisicchio L, Facciabene A, et al. CD4+CD25 + regulatory T-cell-inactivation in combination with adenovirus vaccines enhances T-cell responses and protects mice from tumor challenge. Cancer Gene Ther 14: 201-10 (2007).
155. Colmenero P, Liljestrom P, Joadal M. Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene. Gene Ther 6: 1728-33 (1999).
156. Daemen T, Riezebos-Brilman A, Bungener L, et al. Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7. Vaccine 21: 1082-8 (2003).
157. Rosenberg SA, Zhai Y, Yang JC, et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 90: 1894-900 (1998).
158. Wright P, Braun R, Babiuk L, et al. Adenovirus-mediated TNF-alpha gene transfer induces significant tumor regression in mice. Cancer Biother Radiopharm 14: 49-57 (1999).
159. Martinet O, Ermekova V, Qiao JQ, et al. Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long- term remission of liver metastases in a mouse model. J Natl Cancer Inst 92: 931-6 (2000).
160. Sangro B, Mazzolini G, Ruiz J, et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 22: 1389-97 (2004).
161. Simons JW, Mikhak B, Chang JF, et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 59: 5160-8 (1999).
162. Soiffer R, Lynch T, Mihm M, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent anti-tumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A 95: 13141-6 (1998).
163. Nemunaitis J, Fong T, Robbins JM, et al. Phase I trial of interferon-gamma (IFN-gamma) retroviral vector administered intratumorally to patients with metastatic melanoma. Cancer Gene Ther 6: 322-30 (1999).
164. Soiffer R, Hodi FS, Haluska F, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 21: 3343-50 (2003).
165. Broder H, Anderson A, Odesa SK, Kremen TJ, Liau LM. Recombinant adenovirus-transduced dendritic cell immunization in a murine model of central nervous system tumor. Neurosurg Focus 9: e6 (2000).
166. He Y, Zhang J, Mi Z, Robbins P, Falo LD, Jr. Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J Immunol 174: 3808-17 (2005).
167. Arienti F, Belli F, Napolitano F, et al. Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. Hum Gene Ther 10: 2907-16 (1999).
168. Anson DS. The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery. Genet Vaccines Ther 2: 9 (2004).
169. Quinonez R, Sutton RE. Lentiviral vectors for gene delivery into cells. DNA Cell Biol 21: 937-51 (2002).
170. Zhang WW. Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther 6: 113-38 (1999).
171. Goncalves MA. Adeno-associated virus: from defective virus to effective vector. Virol J 2: 43 (2005).
172. Epstein AL, Marconi P, Arpani R, Manservigi R. HSV-1-derived recombinant and amplicon vectors for gene transfer and gene therapy. Curr Gene Ther 5: 445-58 (2005).
173. Lundstrom K. Semliki Forest virus vectors for gene therapy. Expert Opin Biol Ther 3: 771-7 (2003).